Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2141.2008.07494.x | DOI Listing |
Cureus
May 2024
Laboratory for Clinical Biology, Ziekenhuis Netwerk Antwerpen (ZNA), Antwerp, BEL.
Fy3 is a high-prevalence red blood cell antigen of the Duffy (Fy) blood group system. Anti-Fy3 antibodies are rare and solely arise in individuals with a Duffy null phenotype (Fy(a-b-)), which is a phenotype that mainly occurs in people of African descent. Clinically, anti-Fy3 antibodies can cause both acute and delayed hemolytic transfusion reactions in adults as well as hemolytic disease in fetuses and newborns.
View Article and Find Full Text PDFHaematologica
January 2021
New York Blood Center, Sickle Cell Program, Albert Einstein College of Medicine, Bronx, NY.
Transfus Med
April 2012
Department of Red Cell Immunology (RCI), NHS-Blood and Transplant, Tooting Centre, London, UK.
Background: Hyperhaemolytic transfusion reaction (HHTR) has been well described in patients with sickle cell disease (SCD). It is characterised by a decrease in haemoglobin concentration to levels below those before transfusion and a fall in the absolute reticulocyte count. As red blood cells (RBC) alloantibodies are typically not detected in post-transfusion samples in acute forms of HHTR, we have previously proposed that both the transfused and autologous RBCs cells (HbSS/reticulocytes) are destroyed by activated macrophages.
View Article and Find Full Text PDFImmunohematology
November 2009
Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.
A case of hyperhemolytic transfusion reaction attributable to anti-Fy3 in a 30-year-oldAfricanAmerican woman with a history of sickle cell disease is reported. The patient was admitted for vaso-occlusive sickle cell crisis and received 4 units of packed RBCs secondary to worsening symptomatic anemia (Hb 5.0 g/dL).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!